



BRITISH GENERIC MANUFACTURERS ASSOCIATION

September 3rd, 2015

BGMA welcomes positive appraisal for biosimilar infliximab

In response to NICE publishing final draft guidance confirming its recommended options for rheumatoid arthritis, Warwick Smith, Director General of the British Generic Manufacturers Association, said:

"We welcome NICE's Final Appraisal Determination which recommends biosimilar infliximab as an option for the treatment of severe rheumatoid arthritis following a Multiple Technology Appraisal. NICE also recommends that treatment should be started with the least expensive medicine, which is likely to be the biosimilar. This opens the way for significant savings for the NHS and an increase in the number of patients who can be treated within existing budgets."

ENDS

For further information contact:

Jeremy Durrant, 020 7866 7883 / 07792 918648

Jeremy.durrant@britishgenerics.co.uk

Notes for Editors:

The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.

Generic medicines contain the same active ingredient and are as effective as the equivalent brand and cost much less, making the NHS drugs bill affordable. More than two thirds of all medicines dispensed by the NHS are generics yet they cost only around 29% of the NHS drugs bill, a saving of more than £12.5billion in England & Wales alone. Without generics, the NHS drugs bill would be approximately twice its current level.

We represent the views and interests of our members and industry to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union.

